Síntese de novos compostos acridínicos e mostardas com potencial atividade antitumoral

Abstract

Cancer is a disease that kills the world and it is estimated that in 2030 the incidence of this disease in the world reach 21.4 million new cases with 13.2 million deaths. Due to the resistance, non-selectivity and high cytotoxicity, many of the current drugs produce side effects such as bone marrow depression, sterility, risk of non-lymphocytic leukemia, among others. Thus it is necessary to the development of new anticancer drugs that have less harmful effects. Thus, six new compounds were synthesized, four acridínicos derivative, a derivative of bis (cloroetila) and palladium (II) complex acridínico, whose acronyms, respectively (Acri)2N, AcriPro, ACDMA, ACBr2MAN, (Most)2N and ACDMAPd. All these compounds derived from Schiff base had satisfactory yields and characterized by NMR techniques (1H, 13C, COSY, J solved) spectroscopy in the infrared, mass spectrometry and elemental analysis. The strains used human tumor cells were HT-29 (human colon cancer), MCF-7 (human breast cancer), Hep-2 (human larynx carcinoma), NCI-H292 (carcinoma human pulmonary mucoepidermoid) and HL -60 (acute promyelocytic leukemia) and derivatives AcriPro, ACDMA, (Most)2N and ACDMAPd showed the best results of IC50 for the HL-60 cells.